Radiopharmaceutical Extravasation & Injection Quality

Quick Answer

Extravasation (paravenous deposition of an injected radiopharmaceutical) matters in three ways: it corrupts quantification (retained activity at the injection site is not available to tissues, so SUV and injected-dose–based measures read falsely low), it creates artifacts (a hot injection site and spurious draining-nodal uptake, e.g., axillary/epitrochlear nodes mimicking disease), and — most importantly for therapy — it can deliver a high local radiation dose to skin/soft tissue, risking injury. Prevention (good IV access, patency check, saline flush) and injection-site monitoring are the mainstays; significant therapy extravasations warrant documentation and dosimetric assessment.

Why It Matters

• Diagnostic quantification: SUV assumes the full injected activity is distributed to the body. Activity trapped at the injection site is effectively lost from the denominator's intended distribution, so SUVmax/mean are underestimated — a serial-comparison and response-assessment hazard.
• Image artifacts: an intense injection-site focus, and lymphatic drainage of extravasated tracer to regional nodes (classically axillary from an antecubital/hand injection) that can be mistaken for nodal disease.
• Therapy dosimetry & safety: extravasated Lu-177/Y-90/I-131/Ra-223 deposits high absorbed dose locally (β particles), risking skin erythema, ulceration, or soft-tissue injury — a patient-safety event, not merely a quality issue.

Recognizing & Grading

• On the image: a hot injection site ± draining-node activity; quantitatively, a lower-than-expected SUV or an injection-site count fraction above thresholds (some centers monitor injection-site activity as a QC metric).
• Distinguish true nodal disease from extravasation-related drainage by correlating with the injection side/site and pattern.

Prevention

• Reliable venous access (avoid small/fragile veins, prior-radiation limbs, and the side of prior nodal dissection), confirm patency before injection, and saline flush after.
• Consider contralateral or documented-site injection when nodal assessment of a specific basin is critical.
• Monitor the injection site (visual, and where available, quantitative injection QC).

Management

• Diagnostic extravasation: document; if quantification is critical, re-inject/re-scan or caveat the SUV; interpret any draining nodes cautiously.
• Therapy extravasation: stop, document, and assess; warm compresses and limb elevation promote dispersal/clearance for many agents (agent-specific — some protocols differ), and local dosimetry estimates skin/tissue dose; dermatology/plastics involvement for significant events.

Regulatory Note

Historically diagnostic extravasations were often treated as unavoidable and not reportable, but regulatory attention has increased (notably in the US, where the long-standing reporting exemption for extravasations has been revisited) — significant events, especially therapeutic ones, should be documented and evaluated per current institutional/regulator policy.

Common Pitfalls

• Over-calling axillary/epitrochlear nodal uptake that is actually extravasation drainage from the ipsilateral injection.
• Reporting a falsely low SUV without recognizing injection-site retention.
• Treating a therapy extravasation as a minor issue rather than a potential radiation-injury event.
• Not documenting the injection site/side, precluding later correlation.

Board Pearls

Extravasation (paravenous deposition) falsely lowers SUV (trapped activity isn't distributed as assumed), creates a hot injection site, and can send tracer to draining nodes (classically axillary) that mimic disease. In therapy, extravasated β-emitters (Lu-177/Y-90/I-131) deliver high local skin/soft-tissue dose — a patient-safety event.

The classic artifact is axillary/epitrochlear nodal uptake from an ipsilateral arm/hand injection mistaken for nodal disease — correlate with the injection side/site. Prevention is reliable access, patency check, and saline flush; document the site.

Therapy extravasation management: stop/document, warm compress + elevation (agent-dependent) to aid dispersal, and local dosimetry for skin/tissue dose, with dermatology/plastics for significant injury. Regulatory scrutiny of extravasation reporting has increased — evaluate and document significant events per current policy.

Related Pages

• Physics: SUV harmonization & EARL, dosimetry & theranostics; therapy: radionuclide-therapy toxicity monitoring; pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• An injection-site retention → falsely-low SUV schematic.
• An axillary-drainage artifact teaching pair (extravasation vs true nodal disease).

Self-Check